Despite strong quarter, some wonder how long Gilead can rely on coronavirus drug

Veklury, the antiviral drug for COVID-19, blew past Wall Street expectations in the third quarter, lifting what would have otherwise been a weak earnings season for its developer, Gilead.

During the three-month period, 2 million people received Veklury or a licensed generic version of it, according to Gilead. That use translated to almost $2 billion in sales, nearly triple what analysts had forecasted.